David Issadore

David Issadore develops miniaturized, point-of-care CTC detection devices using magnetic nanoparticle labeling and micro-Hall effect sensors that can enumerate CTCs in clinical settings without centralized laboratory infrastructure. His portable liquid biopsy platforms demonstrate sensitivity comparable to CellSearch while enabling real-time bedside CTC counting. He advances democratization of CTC technology for resource-limited clinical environments.